Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies

Biotechnology Journal

Volumn 6, Issue 1, 2011, Pages 38-44

  Kayser, Veysel ^a   Chennamsetty, Naresh ^a   Voynov, Vladimir ^a   Forrer, Kurt ^b   Helk, Bernhard ^b   Trout, Bernhardt L ^a  

^a USA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody stability; Biochemical engineering; Glycosylation; Human IgG1; Protein aggregation

Indexed keywords

AGGREGATION PROPENSITY; DRUG FORMULATIONS; GLYCOSYLATED; HUMAN IGG1; LONG-TERM STORAGE; MOLECULAR DYNAMICS SIMULATIONS; MOLECULAR LEVELS; PHARMACEUTICAL INDUSTRY; PROTEIN AGGREGATION; TEMPERATURE-INDUCED; THERAPEUTIC MONOCLONAL ANTIBODIES;

BIOCHEMICAL ENGINEERING; ESTERIFICATION; MOLECULAR DYNAMICS; MONOCLONAL ANTIBODIES; STABILITY; SURFACE PLASMON RESONANCE;

GLYCOSYLATION;

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; POLYSACCHARIDE;

ARTICLE; CHEMICAL STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIMULATION; TEMPERATURE MEASUREMENT;

ANTIBODIES, MONOCLONAL; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; PROTEIN STABILITY; TEMPERATURE;

EID: 78651275679     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201000091     Document Type: Article

References (21)

1. Jefferis, R., Criteria for selection of IgG isotype and glycoform of antibody therapeutics. BioProcess Int. 2006, 4, 40-43.
2. Jefferis, R., Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8, 226-234.
3. Krapp, S., Mimura, Y., Jefferis, R., Huber, R., Sondermann, P., Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325, 979-989.
4. Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R. et al., The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 2000, 37, 697-706.
5. Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J. et al., Role of oligosaccharide residues of IgG1-Fc in Fcgamma RIIb binding. J. Biol. Chem. 2001, 276, 45539-45547.
6. Panka, D. J., Glycosylation is influential in murine IgG3 self-association. Mol. Immunol. 1997, 34, 593-598.
7. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., Dwek, R. A., Glycosylation and the immune system. Science 2001, 291, 2370-2376.
8. Ionescu, R. M., Vlasak, J., Price, C., Kirchmeier, M., Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J. Pharm. Sci. 2008, 97, 1414-1426.
9. Gomord, V., Chamberlain, P., Jefferis, R., Faye, L., Biopharmaceutical production in plants: Problems, solutions and opportunities. Trends Biotechnol. 2005, 23, 559-565.
10. Saphire, E. O., Parren, P. W. H. I., Pantophlet, R., Zwick, M. B. et al., Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 2001, 293, 1155-1159.
11. Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J. et al., CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
12. Phillips, J. C., Braun, R., Wang, W., Gumbart, J. et al., Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781-1802.
13. MacKerell, A. D. Jr., Bashford, D., Bellott, M., Dunbrack, R. L. et al., All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
14. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., Klein, M. L., Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
15. Kuttel, M., Brady, J. W., Naidoo, K. J., Carbohydrate solution simulations: Producing a force field with experimentally consistent primary alcohol rotational frequencies and populations. J. Comput. Chem. 2002, 23, 1236-1243.
16. Roberts, C. J., Nonnative protein aggregation: pathways, kinetics, and stability prediction, in: Murphy, R. M., Tsai, A. M. (Eds.), Misbehaving Proteins: Protein (Mis)Folding, Aggregation, and Stability, Springer Science+Business Media, LLC., New York 2006, pp. 17-46.
17. Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. L., Tryptophan-tryptophan energy transfer and classification of tryptophan residues in proteins: Therapeutic monoclonal antibody as a model. J. Fluorescence 2010, DOI:10.1007/s10895-010-0715-0.
18. Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., Trout, B. L., Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol. 2009, 391, 404-413.
19. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. L., Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. USA 2009, 106, 11937-11942.
20. Computational biology: Unstuck by design. Nature 2009, 460, 155-156.
21. Black, S. D., Mould, D. R., Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal. Biochem. 1991, 193, 72-82.